This trial is evaluating whether Health Insurance Navigation Program will improve 2 primary outcomes in patients with Insurance, Health. Measurement will happen over the course of baseline and 5 month follow-up.
This trial requires 80 total participants across 2 different treatment groups
This trial involves 2 different treatments. Health Insurance Navigation Program is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
"Findings suggest that the navigation component had no effect on timely referral from the primary care provider to an oncologist; however, there was a significant increase in the percentage of patients with complete diagnostic evaluation by a specialist by two months after enrollment in the navigation system compared to those who did not participate in the navigation system." - Anonymous Online Contributor
"Clinical trial participation was strongly associated with education, ethnicity, marital status, and cancer specialty knowledge. Cancer specialists were most likely to enroll in a clinical trial; however, those who did not identify as an oncologist may also be eligible for enrollment in a clinical trial." - Anonymous Online Contributor
"Data from a recent study shows that NAP achieves its aims by providing patients with up-to-date information on their medical conditions. It also demonstrates that NAP can help patients navigate through the complicated healthcare system and reduce the cost incurred by patients." - Anonymous Online Contributor
"A health insurance navigation program improves QOL over and above traditional referral and information alone. This improvement occurs despite a similar rate of use of care services by both groups." - Anonymous Online Contributor
"Recent findings demonstrates for the first time that colonoscopy detects cancer at an early stage in only 37% of patients with colorectal cancer. The mean interval between diagnosis of adenoma and diagnosis of rectosigmoid cancers was 11 months, which clearly suggests that metastatic disease can occur after a short period of time from the original tumor. Recent findings of this study point out the need for improved screening programs and earlier detection of colorectal cancer by means of colonoscopy\n" - Anonymous Online Contributor
"There is an increasing trend towards responding patients which suggests that if the patient responds to treatment they can attain long term disease free survival. It is important to note that this is based on patients with stage IIB and stage IIIC CRCs. A cure would require a cure for all CRCs." - Anonymous Online Contributor
"The mean ages at diagnosis and death from colorectal cancer in both males and females are 4 years earlier than what has been reported based on SEER data. This may reflect increased awareness among physicians and decreased mortality." - Anonymous Online Contributor
"Results from a recent paper suggests that familial clustering of colorectal cancer is not due to a single mutation, but rather to complex genetic predisposition involving several genes. Further studies into other candidate genes will be needed to elucidate the actual determinants involved in familial colorectal carcinogenesis." - Anonymous Online Contributor
"The only consistent sign of colorectal cancer is bleeding from the anus or rectum. Other signs may occur, such as abdominal pain, weight loss, itching, decreased appetite, anemia, jaundice, and feeling tired." - Anonymous Online Contributor
"The survival rates for stage III and IV colorectal cancers are better than previously reported. Stage III tumors must be treated aggressively. The prognosis of stage IV disease remains poor. Although the treatment regimen has improved, the overall survival rate remains low. The reasons for this seem multifactorial." - Anonymous Online Contributor
"Data from a recent study suggest that the navigation program has improved patient satisfaction and choice of providers and care coordination. This intervention was associated with improvements in the utilization of preventive services. The health insurance navigator group had higher rates of participation in any screening test and mammogram compared with those who received the control group. However, the relative benefit of navigation was not statistically significant for the most commonly performed screening tests. More research is needed to evaluate the long-term impact on patient outcomes and cost effectiveness of this tool." - Anonymous Online Contributor